Trial · NCT07436611
Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains
NCT07436611, Phase 2, Not yet recruiting, AFT Pharmaceuticals, Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains. Trials, record NCT07436611. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07436611
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains
- NCT number
- NCT07436611
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- AFT Pharmaceuticals, Ltd.
- Conditions
- Port Wine Stains
- Interventions
- Rapamycin cream, Pulsed dyed laser
- First posted
- 2026-02-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinic Objective improvement rating at week 12 | From before laser treatment to the end of treatment after 12 weeks of cream application | The average percentage improvement (0-100% with higher scores being a better outcome) of port wine stain appearance in the cream treated area from baseline to week 12, or at last visit if early withdrawal/discontinuation occurs, as assessed by the principal investigator during the clinic visit. |
| Secondary | Subjective improvement rating (all timepoints) | From before laser treatment to the end of treatment after 12 weeks of cream application | Subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) of port wine stain from baseline after 0, 4, 8 and 12 weeks of treatment. |
| Secondary | Clinic Objective improvement rating (all timepoints) | From before laser treatment to the end of treatment after 12 weeks of cream application | Clinic Objective (investigator) improvement rating (0-100% with higher scores being a better outcome) in port wine stain from baseline after 0, 4, 8 and 12 weeks of treatment |
| Secondary | Photographic Objective improvement rating (all timepoints) | From before laser treatment to the end of treatment after 12 weeks of cream application | Photographic Objective improvement rating (0-100% with higher scores being a better outcome), assessed by a committee of three dermatologists, in port wine stain from baseline after 0, 4, 8 and 12 weeks of treatment |
| Other | Subjective improvement rating change at follow-up | From before laser treatment to follow-up visit (16 weeks) | Subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area from baseline at follow-up visit |
| Other | Subjective improvement rating (post-treatment) | 4 weeks between end of treatment and follow-up visit | Subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area between week 12 and follow-up |
| Other | Clinic Objective improvement rating change at follow-up | From before laser treatment to follow-up visit (16 weeks) | Clinic Objective (investigator) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area from baseline at follow-up visit |
| Other | Clinic Objective improvement rating (post-treatment) | 4 weeks between end of treatment and follow-up visit | Clinic Objective (investigator) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area between week 12 and follow-up |
| Other | Photographic Objective improvement rating change at follow-up | From before laser treatment to follow-up visit (16 weeks) | Photographic Objective improvement rating (0-100% with higher scores being a better outcome), assessed by a committee of three dermatologists, change of cream treated area from baseline at follow-up visit |
| Other | Photographic Objective improvement rating (post-treatment) | 4 weeks between end of treatment and follow-up visit | Photographic Objective improvement rating (0-100% with higher scores being a better outcome), assessed by a committee of three dermatologists, change of cream treated area between week 12 and follow-up |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07436611
GET https://conductscience.org/api/trials/v1/NCT07436611/registered